Roche

@Roche

We advance science so that we all have more time with the people we love. Read our community guidelines: go.roche.com/CG

Basel, Switzerland

Roche
@Roche
8h
#MEDIA – We are pleased that the U.S. FDA has accepted the new drug application for our investigational medicine for both relapsing and primary progressive multiple sclerosis. Read here 👉 spkl.io/60187p5Iw #multiplesclerosis #MS
2
Roche
@Roche
11h
Weak circulating tumor DNA (ctDNA) signals remain a primary bottleneck in minimal residual disease research. Roche’s sequencing by expansion (SBX) achieves the throughput necessary to bypass standard resolution limits. Discover more: go.roche.com/xsbxgen2 (Research use only)
1
Roche
@Roche
Sep 25
Better cancer outcomes shouldn't demand bigger budgets—they demand smarter innovation. Reflecting on this year's World Cancer Congress, the path forward is clear: the real cost of cancer isn’t just treatment, but the time stolen from families when care comes too late. By
2
Roche
@Roche
Sep 24
Breast cancer care shouldn't depend on where you live. At this year's World Cancer Congress, the message was clear: regional collaboration is key to ensuring every woman gets the care she deserves, no matter where she lives. By working across borders to bring diagnosis and
3
Roche
@Roche
Sep 23
#MEDIA – We are excited to share positive interim phase III results in IgA nephropathy, a progressive kidney disease that can lead to kidney failure. Read more here 👉 spkl.io/60157TnLZ $ROG $RHHBY
1